ADREX pharma

Certificate of Analysis CANNABIS Flos
Batch: 50504

Product	**Dank Craft 30 UC CAN**
Country	Germany
Manufacturing license No.	DE_RP_01_MIA_2025_0043
Potency	Δ^9-Tetrahydrocannabinol approx. 30%
	Cannabidiol ≤ 1%
Dosage form	Cannabis Flowers, dried; cultivar: Ultra Coconut
Pack size	100g pouches
Batch	50504

Manufacturing date	17.12.2025

Test	Method	Specification	Result	Complies
Identification A	EP 3028	Complies with the description of the monograph	Complies	YES
Identification B	EP 3028	Complies with the description of the monograph	Complies	YES
Identification C	EP 3028 (TLC)	Complies with the description of the monograph	Complies	YES
Assay	EP 3028 (HPLC)	CBD total: ≤ 1.0% THC total: 27.0% – 33.0%	< 0.1 % 27.1 %	YES
CBN total	EP 3028 (HPLC)	CBN: ≤ 1.0%	0.2 %	YES
Foreign matter	EP 3028	≤ 2.0% No seeds No leaves >1.0 cm	< 2 % Complies Complies	YES
Loss on drying	EP 3028	≤ 12.0%	8.9 %	YES
Pesticides*	EP 2.8.13	Complies with the requirements EP 2.8.13	Complies	YES
Aflatoxins	EP 2.8.18	B1: ≤ 2 µg/kg Sum B1, B2, G1, G2: ≤ 4 µg/kg	n.n. n.n.	YES
Ochratoxin A*	EP 2.8.22	≤ 20 µg/kg	n.n.	YES
Heavy metals analysis*	EP 2.4.27	Arsenic: ≤ 0.2 ppm Cadmium: ≤ 0.3 ppm Lead: ≤ 0.5 ppm Mercury: ≤ 0.1 ppm	< 0.1 ppm < 0.1 ppm < 0.1 ppm < 0.05 ppm	YES
Microbiological purity		*EP 5.1.8C*		YES
TAMC	EP 2.6.12	≤ 500 000 cfu/g	< 100 cfu/g	
TYMC		≤ 50 000 cfu/g	35 cfu/g	
Bile tolerant gram neg. bacteria	EP 2.6.31	≤ 10 000 cfu/g	< 10 cfu/g	
Escherichia coli		*absent / 1 g*	absent /g	
Salmonella species		*absent / 25 g*	absent /25g	

n.n. = below limit of quantitation

Examined by:
QSI GmbH, Flughafendamm 9a, 28199 Bremen
* Eurofins BioPharma Product Testing Toronto Inc., Canada

Expiry date	**05/2026**

I hereby declare that this batch of the medicinal product has been manufactured and tested in compliance with the applicable GMP regulations and in accordance with the master documents approved by the client and has been tested in compliance with recognized pharmaceutical regulations pursuant to § 6 No. 3 ApBetrO and is hereby released for marketing pursuant § 16 AMWHV.
All starting materials and intermediate products used have been tested and were approved.

18.12.2025 [redacted]

Dr. Klaus-Uwe Pechar

Date / Signature Qualified Person

ADREXpharma GmbH, Jakob- Hasslacher- Str. 4 56070 Koblenz
HRB 26108, Koblenz

Steuer Nummer 22/650/01532
VAT Nummer DE 815 754 017

T +49 261 450 98 20
F +49 261 450 98 210
info@adrexpharma.com
www.adrexpharma.com
Gerichtsstand: Koblenz

Sparkasse Koblenz
IBAN: DE93 5705 0120 0000 2710 80
BIC: MALADE51KOB

GF: Nicole Broockmann